Skip to main content
Erschienen in: Strahlentherapie und Onkologie 2/2018

30.10.2017 | Original Article

Outcome and prognostic factors in single brain metastases from small-cell lung cancer

verfasst von: Dr. Denise Bernhardt, Sebastian Adeberg, Farastuk Bozorgmehr, Nils Opfermann, Juliane Hörner-Rieber, Laila König, Jutta Kappes, Michael Thomas, Andreas Unterberg, Felix Herth, Claus Peter Heußel, Arne Warth, Jürgen Debus, Martin Steins, Stefan Rieken

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Whole brain radiation therapy (WBRT) is historically the standard of care for patients with brain metastases (BM) from small-cell lung cancer (SCLC), although locally ablative treatments are the standard of care for patients with 1–4 BM from other solid tumors. The objective of this analysis was to find prognostic factors influencing overall survival (OS) and intracranial progression-free survival (iPFS) in SCLC patients with single BM (SBM) treated with WBRT.

Methods

A total of 52 patients were identified in the authors’ cancer center database with histologically confirmed SCLC and contrast-enhanced magnet resonance imaging (MRI) or computed tomography (CT), which confirmed SBM between 2006 and 2015 and were therefore treated with WBRT. A Kaplan-Meier survival analysis was performed for OS analyses. The log-rank (Mantel-Cox) test was used to compare survival curves. Univariate Cox proportional-hazards ratios (HRs) were used to assess the influence of cofactors on OS and iPFS.

Results

The median OS after WBRT was 5 months and the median iPFS after WBRT 16 months. Patients that received surgery prior to WBRT had a significantly longer median OS of 19 months compared to 5 months in the group receiving only WBRT (p = 0.03; HR 2.24; 95% confidence interval [CI] 1.06–4.73). Patients with synchronous disease had a significantly longer OS compared to patients with metachronous BM (6 months vs. 3 months, p = 0.005; HR 0.27; 95% CI 0.11–0.68). Univariate analysis for OS revealed a statistically significant effect for metachronous disease (HR 2.25; 95% CI 1.14–4.46; p = 0.019), initial response to first-line chemotherapy (HR 0.58; 95% CI 0.35–0.97; p = 0.04), and surgical resection (HR 0.36; 95% CI 0.15–0.88; p = 0.026). OS was significantly affected by metachronous disease in multivariate analysis (HR 2.20; 95% CI 1.09–4.45; p = 0.028).

Conclusions

Univariate analysis revealed that surgery followed by WBRT can improve OS in patients with SBM in SCLC. Furthermore, synchronous disease and response to initial chemotherapy appeared to be major prognostic factors. Multivariate analysis revealed metachronous disease as a significantly negative prognostic factor on OS. The value of WBRT, stereotactic radiosurgery (SRS), or surgery alone or in combination for patients with a limited number of BM in SCLC should be evaluated in further prospective clinical trials.
Literatur
5.
17.
Zurück zum Zitat Postmus PE, Haaxma-Reiche H, Smit EF, Groen HJM, Karnicka H, Lewinski T et al (2000) Treatment of brain metastases of small-cell lung cancer: comparing teniposide and teniposide with whole-brain radiotherapy—a phase III study of the European organization for the research and treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 18:3400–3408 (http://jco.ascopubs.org/content/18/19/3400.long. Accessed 23 August 2016)CrossRefPubMed Postmus PE, Haaxma-Reiche H, Smit EF, Groen HJM, Karnicka H, Lewinski T et al (2000) Treatment of brain metastases of small-cell lung cancer: comparing teniposide and teniposide with whole-brain radiotherapy—a phase III study of the European organization for the research and treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 18:3400–3408 (http://​jco.​ascopubs.​org/​content/​18/​19/​3400.​long. Accessed 23 August 2016)CrossRefPubMed
24.
Zurück zum Zitat Shibamoto Y, Baba F, Oda K, Hayashi S, Kokubo M, Ishihara S‑I et al (2008) Incidence of brain atrophy and decline in mini-mental state examination score after whole-brain radiotherapy in patients with brain metastases: a prospective study. Int J Radiat Oncol Biol Phys 72:1168–1173 (http://www.ncbi.nlm.nih.gov/pubmed/18495375. Accessed 15 September 2016)CrossRefPubMed Shibamoto Y, Baba F, Oda K, Hayashi S, Kokubo M, Ishihara S‑I et al (2008) Incidence of brain atrophy and decline in mini-mental state examination score after whole-brain radiotherapy in patients with brain metastases: a prospective study. Int J Radiat Oncol Biol Phys 72:1168–1173 (http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​18495375. Accessed 15 September 2016)CrossRefPubMed
26.
Zurück zum Zitat Soffietti R, Kocher M, Abacioglu UM, Villa S, Fauchon F, Baumert BG et al (2013) A European Organisation for Research and Treatment of Cancer phase III trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery: quality-of-life. J Clin Oncol 31:65–72 (Available: http://www.ncbi.nlm.nih.gov/pubmed/23213105. Accessed 15 September 2016)CrossRefPubMed Soffietti R, Kocher M, Abacioglu UM, Villa S, Fauchon F, Baumert BG et al (2013) A European Organisation for Research and Treatment of Cancer phase III trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery: quality-of-life. J Clin Oncol 31:65–72 (Available: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​23213105. Accessed 15 September 2016)CrossRefPubMed
27.
Metadaten
Titel
Outcome and prognostic factors in single brain metastases from small-cell lung cancer
verfasst von
Dr. Denise Bernhardt
Sebastian Adeberg
Farastuk Bozorgmehr
Nils Opfermann
Juliane Hörner-Rieber
Laila König
Jutta Kappes
Michael Thomas
Andreas Unterberg
Felix Herth
Claus Peter Heußel
Arne Warth
Jürgen Debus
Martin Steins
Stefan Rieken
Publikationsdatum
30.10.2017
Verlag
Springer Berlin Heidelberg
Erschienen in
Strahlentherapie und Onkologie / Ausgabe 2/2018
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-017-1228-4

Weitere Artikel der Ausgabe 2/2018

Strahlentherapie und Onkologie 2/2018 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.